Literature DB >> 33277347

Physiologically Based Pharmacokinetics of Lysosomotropic Chloroquine in Rat and Human.

Xin Liu1, William J Jusko2.   

Abstract

A semimechanistic physiologically based pharmacokinetic (PBPK) model for chloroquine (CQ), a highly lysosomotropic weak base, was applied to digitized rat and human concentration versus time data. The PBPK model in rat featured plasma and red blood cell (RBC) concentrations, extensive and apparent nonlinear tissue distribution, fitted hepatic and renal intrinsic clearances, and a plasma half-life of about 1 day. Tissue-to-plasma CQ ratios at 50 hours after dosing were highest in lung, kidney, liver, and spleen (182-318) and lower in heart, muscle, brain, eye, and skin (11-66). The RBC-to-plasma ratio of 11.6 was assumed to reflect cell lipid partitioning. A lysosome-based extended model was used to calculate subcellular CQ concentrations based on tissue mass balances, fitted plasma, interstitial and free cytosol concentrations, and literature-based pH and pKa values. The CQ tissue component concentrations ranked as follows: lysosome > > acidic phospholipid > plasma = interstitial = cytosol ≥ neutral lipids. The extensive lysosome sequestration appeared to change over time and was attributed to lowering pH values caused by proton pump influx of hydrogen ions. The human-to-rat volume of distribution (Vss) ratio of 7 used to scale rat tissue partitioning to human along with estimation of hepatic clearance allowed excellent fitting of oral-dose PK (150-600 mg) of CQ with a 50-day half-life in humans. The prolonged PK of chloroquine was well characterized for rat and human with this PBPK model. The calculated intratissue concentrations and lysosomal effects have therapeutic relevance for CQ and other cationic drugs. SIGNIFICANCE STATEMENT: Sequestration in lysosomes is a major factor controlling the pharmacokinetics and pharmacology of chloroquine and other cationic drugs. This report provides comprehensive physiologic modeling of chloroquine distribution in tissues and overall disposition in rat and human that reveals expected complexities and inferences related to its subcellular association with various tissue components.
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33277347      PMCID: PMC7841423          DOI: 10.1124/jpet.120.000385

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  57 in total

1.  Influence of lipophilicity and lysosomal accumulation on tissue distribution kinetics of basic drugs: a physiologically based pharmacokinetic model.

Authors:  K Yokogawa; J Ishizaki; S Ohkuma; K Miyamoto
Journal:  Methods Find Exp Clin Pharmacol       Date:  2002-03

2.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions.

Authors:  Trudy Rodgers; Malcolm Rowland
Journal:  J Pharm Sci       Date:  2006-06       Impact factor: 3.534

3.  Time-dependent effects of chloroquine on pH of hepatocyte lysosomes.

Authors:  P S Tietz; K Yamazaki; N F LaRusso
Journal:  Biochem Pharmacol       Date:  1990-09-15       Impact factor: 5.858

4.  Quantitative modeling of selective lysosomal targeting for drug design.

Authors:  Stefan Trapp; Gus R Rosania; Richard W Horobin; Johannes Kornhuber
Journal:  Eur Biophys J       Date:  2008-05-27       Impact factor: 1.733

5.  Tissue distribution of chloroquine in rats in the course of long-term application.

Authors:  M Grundmann; I Mikulíkrová; P Vrublovský
Journal:  Arch Int Pharmacodyn Ther       Date:  1972-05

6.  Studies of the metabolism of some compounds of the 4-amino-7-chloroquinoline series.

Authors:  E W McChesney; W D Conway; W F Banks; J E Rogers; J M Shekosky
Journal:  J Pharmacol Exp Ther       Date:  1966-03       Impact factor: 4.030

7.  Incorporation of lysosomal sequestration in the mechanistic model for prediction of tissue distribution of basic drugs.

Authors:  Frauke Assmus; J Brian Houston; Aleksandra Galetin
Journal:  Eur J Pharm Sci       Date:  2017-08-18       Impact factor: 4.384

8.  A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers.

Authors:  S E Tett; D J Cutler; R O Day; K F Brown
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

9.  The pharmacokinetics of promazine and its metabolites after acute and chronic administration to rats--a comparison with the pharmacokinetics of imipramine.

Authors:  W Daniel; M Syrek; L Janczar; J Boksa
Journal:  Pol J Pharmacol       Date:  1995 Mar-Apr

10.  Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats.

Authors:  J Emami; F M Pasutto; F Jamali
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

View more
  2 in total

1.  A Capillary Electrophoresis-Based Method for the Measurement of Hydroxychloroquine and Its Active Metabolite Desethyl Hydroxychloroquine in Whole Blood in Patients with Rheumatoid Arthritis.

Authors:  Salvatore Sotgia; Angelo Zinellu; Nicola Mundula; Arduino A Mangoni; Ciriaco Carru; Gian Luca Erre
Journal:  Molecules       Date:  2022-06-17       Impact factor: 4.927

2.  A permeability- and perfusion-based PBPK model for improved prediction of concentration-time profiles.

Authors:  Ken Korzekwa; Casey Radice; Swati Nagar
Journal:  Clin Transl Sci       Date:  2022-05-31       Impact factor: 4.438

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.